Redeye returns with an update on Saniona. We are impressed by the company’s deal-making capabilities, having secured two landmark licensing agreements within the last twelve months. With a robust cash position and multiple programs approaching the clinic, we have incorporated several new projects into our valuation. Together with the Jazz agreement, this results in an increased valuation range.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/